Ayberk Bayramgil

12PUBLICATIONS
106CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical biochemistry - proteins and peptides (incl. medical proteomics)Predictive and prognostic markersAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

|May 27, 2026
Prognostic Impact of Ectopic Fat Deposition Within the Psoas Muscle in Patients with Stage IV Pancreatic Cancer Receiving Systemic Chemotherapy.

|Mar 28, 2026
Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR.

Ayberk Bayramgil, Mehmet Haluk Yücel, Ezgi Turkoglu

|Mar 14, 2026
Association of Post-Neoadjuvant Chemotherapy MRI and 18F-FDG PET/CT Findings with Tumor Response and Prognosis in Breast Cancer.

Burçin Çakan Demirel, Semra Taş, Ayberk Bayramgil

|Jan 10, 2026
Inflammation-Related Parameters in Lung Cancer Patients Followed in the Intensive Care Unit.

Burcu Tunay, Omer Fatih Olmez, Ahmet Bilici

Pageof 2

Frequent Collaborators

5 joint publications

Yunus Emre Altıntaş

3 joint publications

Ahmet Bilici

3 joint publications

Musa Barış Aykan

3 joint publications

Burcin Cakan Demirel